CPI-482 / Novartis - LARVOL DELTA

Therapeutic potential of CPI-482 for AML and post-MPN AML (YouTube) - "Raajit Rampal, MD, PhD...discusses a study investigating the therapeutic potential of the lysine-specific demethylase 1 (LSD1) inhibitor CPI-482 for treating acute myeloid leukemia (AML) and post-myeloproliferative neoplasm (MPN) AML....Finally, it was possible to observe restoration of normal hematopoiesis in the mice treated with CPI-482. This data supports the potential therapeutic impact of the LSD1 inhibitor CPI-482 in AML in the context of the JAK2V617F mutation. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020."

Video

[VIRTUAL] LSD1 Inhibitor CPI-482 Shows Efficacy and Prolongs Survival in Mouse Models of AML and Post-MPN AML in the Context of Constitutive JAK-STAT Pathway Activation (ASH 2020) - "Mice were randomized to treatment with vehicle, Ruxolitinib (60mg/kg twice daily) or CPI-482 (60mg/kg weekly). These data provide support for a potential therapeutic impact of the LSD1 inhibitor CPI-482 in AML and sAML in the context of the JAK2V617F mutation, and thus extend the previous findings that LSD1 inhibitors may have utility in JAK2V617F mutated malignant proliferative neoplasms. Given the pressing need for new therapies for sAML which evolves from a pre-existing MPN, we believe these data form the rationale for a mechanism based clinical trial in this adverse risk myeloid malignancy."

Acute Myelogenous Leukemia • Fibrosis • Gene Therapies • Hematological Disorders • Hematological Malignancies • Immunology • Inflammation • Leukemia • Oncology • Transplantation • HOXA9 • JAK2 • TP53